Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro (ALZN) announced it has regained compliance with Nasdaq's listing standards, meeting the minimum stockholders' equity requirement of $2.5M. The company reported $5.8M in equity as of July 31, 2026. This follows a previous non-compliance notice in March 2026, which the company addressed with a submitted plan. The CEO expressed focus on advancing clinical trials for AL001 in partnership with Massachusetts General Hospital.

Original reporting
Published Sep 16, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards — source image
Decision brief

The 30-second read

$ALZNBullishLow
01

Why it matters

Regaining Nasdaq compliance eliminates a potential delisting threat, which could stabilize the share price.

02

Market read

The news is a primary corporate action for ALZN, removing a regulatory risk but offering limited immediate trading impetus.

03

What to watch

The announcement does not address upcoming clinical trial results, which remain the primary catalyst.

Relevance 5/10Novelty 6/10Timing: Sept 16 2026 (same‑day announcement)

Background

Alzamend Neuro is a clinical‑stage biopharma focused on neuro‑psychiatric disorders.

Company-level read

Ticker impact

$ALZNBullishMedium confidence
Context

Alzamend Neuro announced it regained compliance with Nasdaq Listing Rule 5550(b)(1) after meeting the $2.5M equity requirement.

Expected impact

Potential modest upside as investors view the listing security favorably.

Evidence & confidence

The company cleared a regulatory hurdle; no new financing or product data was disclosed.

Market effects

May improve perception of compliance risk for small‑cap biotech listings.

Limited to US Nasdaq market; no broader regional effect.

Minimal global impact; primarily a company‑specific regulatory update.

Counterpoint

Investors may view the compliance fix as a one‑time event and remain cautious on valuation.

Key entities

  • Alzamend Neuro, Inc.

    Clinical‑stage biopharma listed on Nasdaq (ALZN).

  • Nasdaq Listing Qualifications Staff

    Issued the compliance notice confirming ALZN meets equity requirements.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.